The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Frontotemporal Dementia: A Randomised, Controlled Trial with Trazodone
Abstract
Behavioural troubles due to frontotemporal dementia (FTD) are difficult to treat. The serotonergic system is associated with frontal lobes, the degeneration of which contributes to FTD. Trazodone increases the extracellular 5-HT levels in the frontal cortex. In a randomised, double-blind, placebo-controlled cross-over study, we investigated the effect of trazodone. There was a significant decrease in the Neuropsychiatry Inventory (NPI) total score with trazodone (p = 0.028) in the 26 evaluable patients. A decrease of more than 50% in the NPI score was observed in 10 patients with trazodone. This improvement was mainly based on the improvement of 4 items of the scale (irritability, agitation, depressive symptoms and eating disorders). The Mini-Mental State Examination was not modified and trazodone was well tolerated. Results of this first placebo-controlled trial suggest that trazodone is an effective treatment for the behavioural symptoms of FTD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Treatment of agitation in AD: A randomized, placebo-controlled clinical trial
Teri, L., Logsdon, R. G., Peskind, E., Raskind, M., Weiner, M. F., Tractenberg, R. E., Foster, N. L., Schneider, L. S., Sano, M., Whitehouse, P., et al. (2000) · Neurology · doi:10.1212/wnl.55.9.1271 · Cited by 330
Frontotemporal Dementia: Treatment Response to Serotonin Selective Reuptake Inhibitors
Swartz, J. R., Miller, B. L., Lesser, I. M., & Darby, A. L. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0506 · Cited by 250
Frontotemporal Dementia: Paroxetine as a Possible Treatment of Behavior Symptoms
Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., & Bava, A. (2003) · European Neurology · doi:10.1159/000067021 · Cited by 172
Neurochemical Features of Frontotemporal Dementia
PROCTER, A. W., Qurne, M., & Francis, P. T. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051219 · Cited by 125
Frontotemporal Behavioral Scale
Lebert, F., Pasquier, F., Soûliez, L., & Petit, H. (1998) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199812000-00014 · Cited by 121
Self-citationAltered Serotonergic and Cholinergic Synaptic Markers in Pick's Disease
Sparks, D. L., & Markesbery, W. R. (1991) · Archives of Neurology · doi:10.1001/archneur.1991.00530200032014 · Cited by 114
Decreased monoamine metabolites in frontotemporal dementia and Alzheimer’s disease
Sjögren, M. J. C., Minthon, L., Passant, U., Blennow, K., & Wallin, A. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00086-4 · Cited by 83
Trazodone in the treatment of behaviour in frontotemporal dementia
Lebert, F., & Pasquier, F. (1999) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/(sici)1099-1077(199906)14:4<279::aid-hup89>3.0.co;2-1 · Cited by 31
Self-citation
Cited by
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationBang, J., Spina, S., & Miller, B. L. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00461-4 · Cited by 1,144
Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases
Erkkinen, M. G., Kim, M.-O., & Geschwind, M. D. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033118 · Cited by 1,124
Semantic dementia: a unique clinicopathological syndrome
Hodges, J. R., & Patterson, K. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70266-1 · Cited by 772
Neary, D., Snowden, J., & Mann, D. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70223-4 · Cited by 526
Frontotemporal Lobar Degeneration: Epidemiology, Pathophysiology, Diagnosis and Management
Rabinovici, G. D., & Miller, B. L. (2010) · CNS Drugs · doi:10.2165/11533100-000000000-00000 · Cited by 501
Olney, N. T., Spina, S., & Miller, B. L. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.008 · Cited by 419
O’Brien, J. T., Holmes, C., Jones, M., Jones, R., Livingston, G., McKeith, I., Mittler, P., Passmore, P., Ritchie, C., Robinson, L., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116680924 · Cited by 354
EFNS‐ENS Guidelines on the diagnosis and management of disorders associated with dementia
Sorbi, S., Hort, J., Erkinjuntti, T., Fladby, T., Gainotti, G., Gurvit, H., Nacmias, B., Pasquier, F., Popescu, B. O., Rektorova, I., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03784.x · Cited by 306
Self-citationA systematic review of neurotransmitter deficits and treatments in frontotemporal dementia
Huey, E. D., Putnam, K. T., & Grafman, J. (2006) · Neurology · doi:10.1212/01.wnl.0000191304.55196.4d · Cited by 299
Halliday, M., Radford, H., Zents, K. A. M., Molloy, C., Moreno, J. A., Verity, N. C., Smith, E., Ortori, C. A., Barrett, D. A., Bushell, M., et al. (2017) · Brain · doi:10.1093/brain/awx074 · Cited by 293
Warren, J. D., Rohrer, J. D., & Rossor, M. N. (2013) · BMJ · doi:10.1136/bmj.f4827 · Cited by 292
Rascovsky, K., Hodges, J. R., Kipps, C. M., Johnson, J. K., Seeley, W. W., Mendez, M. F., Knopman, D., Kertesz, A., Mesulam, M., Salmon, D. P., et al. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31815c3445 · Cited by 260
Galantamine in Frontotemporal Dementia and Primary Progressive Aphasia
Kertesz, A., Morlog, D., Light, M., Blair, M., Davidson, W., Jesso, S., & Brashear, R. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000113034 · Cited by 217
Frontotemporal lobar degeneration
Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., et al. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00447-0 · Cited by 178
Watt, J. A., Goodarzi, Z., Veroniki, A. A., Nincic, V., Khan, P. A., Ghassemi, M., Lai, Y., Treister, V., Thompson, Y., Schneider, R., et al. (2021) · BMJ · doi:10.1136/bmj.n532 · Cited by 143
Frontotemporal Lobar Degeneration: Epidemiology, Pathology, Diagnosis and Management
Seltman, R. E., & Matthews, B. R. (2012) · CNS Drugs · doi:10.2165/11640070-000000000-00000 · Cited by 132
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., & Imbimbo, B. P. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0330-x · Cited by 122
Improving response inhibition systems in frontotemporal dementia with citalopram
Hughes, L. E., Rittman, T., Regenthal, R., Robbins, T. W., & Rowe, J. B. (2015) · Brain · doi:10.1093/brain/awv133 · Cited by 100
“SSRIs have been tested in a small number of open-label studies of bvFTD (for review see Boxer and Boeve, 2007; Freedman, 2007) with promising results, such as improve- ment on the Neuropsychiatric Inventory (Swartz et al., 1997; Lebert et al., 2004; Herrmann et al., 2012”
BackgroundDucharme, S., Price, B. H., Larvie, M., Dougherty, D. D., & Dickerson, B. C. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14101248 · Cited by 98
Toward a glutamate hypothesis of frontotemporal dementia
Benussi, A., Alberici, A., Buratti, E., Ghidoni, R., Gardoni, F., Di Luca, M., Padovani, A., & Borroni, B. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00304 · Cited by 90
Behavioral disturbances in the course of frontotemporal dementia
Diehl-Schmid, J., Pohl, C., Perneczky, R., Förstl, H., & Kurz, A. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000095625 · Cited by 72
Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance
Costello, H., Roiser, J. P., & Howard, R. (2023) · Psychological Medicine · doi:10.1017/s003329172200397x · Cited by 60
“…RCTs of SSRIs (RCTs) found opposing results in terms of efficacy (Deakin, Rahman, Nestor, Hodges, & Sahakian, 2004; Moretti, Torre, Antonello, Cazzato, & Bava, 2003), though one trial of trazodone in 26 patients reported reduced depressive symptoms (Lebert, Stekke, Hasenbroekx, & Pasquier, 2004).”
Advances in treatment of frontotemporal dementia
Magrath Guimet, N., Zapata-Restrepo, L. M., & Miller, B. L. (2022) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.21060166 · Cited by 52
Pharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia
Le, C., & Finger, E. (2021) · CNS Drugs · doi:10.1007/s40263-021-00854-5 · Cited by 26
Sommerlad, A., Werbeloff, N., Perera, G., Smith, T., Costello, H., Mueller, C., Kormilitzin, A., Broadbent, M., Nevado‐Holgado, A., Lovestone, S., et al. (2022) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5625 · Cited by 14
Metadata
- Authors
- Lebert, F., Stekke, W., Hasenbroekx, C., & Pasquier, F.
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2004
- Volume
- 17
- Issue
- 4
- Pages
- 355-359
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- OpenAlex
- W1968385408
- Cited by
- 382
- References
- 10
- FWCI
- 9.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.